CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Over 42,000 delegates from across the globe registered to attend the European Academy of Neurology Virtual Meeting, 23-26 May 2020, making it the largest ever neurology congress.
Reassuring safety data have been reported in patients with cardiovascular (CV) disease treated with erenumab or fremanezumab.1-3 In a post-hoc analysis of long-term erenumab data from 2443 patients with episodic or chronic migraine with or without aura, the vascular safety profile was similar in patients with/without a history of aura and was comparable to that …
Read more »Extensive data from the double-blind and open-label phases of the Phase 3 CONQUER study of galcanezumab in treatment-resistant migraine have highlighted the drug’s positive effects on a broad range of outcomes, including monthly migraine headache days (MMHD), >50% responder rates, health-related quality of life, work productivity and inter-ictal burden.1-4 In an analysis of 186/462 (40.3%) …
Read more »Eptinezumab reduces migraine days in patients with chronic migraine (CM) and medication-overuse headache (MOH) as early as day 1 of treatment and effects are sustained through 24 weeks of therapy, according to data from the PROMISE-2 study.1 Of 1072 patients with CM who were treated, 431 (40.2%) were diagnosed with MOH. During weeks 1-12, monthly …
Read more »Real world data on the use of erenumab in Germany demonstrate the importance of gaining both the patient and physician perspectives on the impact of treatment. Comparative results from online surveys (PERISCOPE in 90 patients and TELESCOPE in 45 physicians documenting 542 patients) indicate both differences and overlap in experiences of erenumab treatment. In PERISCOPE, …
Read more »Fremanezumab was effective and improved quality of life and work productivity in patients ≥60 years of age, according to analyses of pooled data from phase 3 trials in episodic and chronic migraine (HALO EM, HALO CM, and FOCUS).1,2 In 246 patients ≥60, mean monthly migraine days (MMDs) were reduced by 4.3 days with quarterly fremanezumab …
Read more »microRNA expression patterns may have potential as biomarkers for medication overuse (MO) in patients with chronic migraine.1 Results of a study of plasma CGRP levels and microRNA expression patterns before and after detoxification showed that, while changes in CGRP were indicative of migraine severity, microRNA changes were aligned with MO. Dr Chiara Demartini, from the …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
